Advertisement

Neoadjuvant Radiotherapy

  • Te Vuong
  • Aurelie Garant
Chapter

Abstract

Over the last two decades, radiation treatment has evolved significantly, not only through its application in serial randomized clinical trials but in many other aspects. One of these key factors is modern imaging, such as computerized tomography and magnetic resonance imaging (MRI), which has become an essential component in determining treatment strategies. In the era of total mesorectal excision surgery (TME), preoperative radiotherapy (RT) reduces local recurrence and can be given either with long-course RT with 5-fluorouracil (5-FU)-based regimen or short-course RT (SCRT). For patients with positive circumferential radial margin (CRM), tumor down-staging is highly desirable, and SCRT is not as effective to prevent local recurrence. Contemporary pattern of recurrence suggests that it is possible to lower the upper limit of the treatment field level. In an effort to reduce radiation-related toxicity, field adjustments along with exploration of new radiation targeted radiation modalities are desirable.

Keywords

Radiation therapy Local control Randomized clinical trials Treatment-related toxicities Overall survival Treatment volumes Radiation modalities 

References

  1. 1.
    Mercury Study group. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer surgery. BMJ. 2006;333(7572):779.CrossRefPubMedCentralGoogle Scholar
  2. 2.
    Beet-Tan RG, Beets GL, Vliegen RF, et al. Accuracy of magnetic resonance imaging in prediction of tumor free resection margin in rectal cancer surgery. Lancet. 2001;7(9255):497–504.CrossRefGoogle Scholar
  3. 3.
    Swedish rectal cancer Trial. Improved survival with pre operative radiotherapy radiotherapy in resectable rectal cancer. N Engl J Med. 1997;336(14):980–7.CrossRefGoogle Scholar
  4. 4.
    Kapiteijn E, Marijnen CAM, Nagtegall ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638–46.CrossRefPubMedGoogle Scholar
  5. 5.
    Gijn WV, Marijnen CAM, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12:575–82.CrossRefPubMedGoogle Scholar
  6. 6.
    Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009;373:811–20.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Den Dulk M, Collette L, Van de Velde CJM, et al. Quality of surgery in T3-4 rectal cancer: involvement of circumferential resection margin not influenced by preoperative treatment. Results from EORTC trial 22921. Eur J Cancer. 2007;43(12):1821–8.CrossRefGoogle Scholar
  8. 8.
    Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93:1215–23.CrossRefPubMedGoogle Scholar
  9. 9.
    Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114–23.CrossRefPubMedGoogle Scholar
  10. 10.
    Gerard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24:4620–5.CrossRefPubMedGoogle Scholar
  11. 11.
    De Caluwe L, Van Nieuwenhove Y, Ceelen WP, et al. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev. 2013;2:CD006041.Google Scholar
  12. 12.
    Ngan SY, Burmaister B, Fisher RJ, et al. Randomized trial of short-course radiotherapy versus long course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: trans-tasman radiation oncology group trial 01.04. J Clin Oncol. 2012;30:3827–33.CrossRefPubMedGoogle Scholar
  13. 13.
    Sauer R, Becker H, Hohenberger W, et al. Pre operative versus postoperative chemo-radiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.CrossRefPubMedGoogle Scholar
  14. 14.
    Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29:2773–80.CrossRefPubMedGoogle Scholar
  15. 15.
    Gerard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 2010;28:1638–44.CrossRefPubMedGoogle Scholar
  16. 16.
    O'Connell MJ, Colangelo LH, Beart RW, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from national surgical adjuvant breast and bowel project trial R-04. J Clin Oncol. 2014;32(18):1927–34.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Rodel C, Graeven U, Fietkau R, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16(8):979–89. ePub July 2015CrossRefPubMedGoogle Scholar
  18. 18.
    Schmoll HJ, Haustermans K, Price T, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: response to the local treatment after chemoradiation and surgery as secondary endpoint. Eur J Cancer. 2013;49:S482–2.Google Scholar
  19. 19.
    Nijkamp J, Kusters M, Beets-tan RH, et al. Three-dimensional analysis of recurrence patterns in rectal cancer: the cranial border in hypofractionated preoperative radiotherapy can be lowered. Int J Radiat Oncol Biol Phys. 2011;80(1):103–10.CrossRefPubMedGoogle Scholar
  20. 20.
    Syk E, Torkzad M, Blomqvist P, et al. Local recurrence in rectal cancer: anatomic localization and effect on radiation target. Int J Radiat Oncol Biol Phys. 2008;73(3):658–64.CrossRefGoogle Scholar
  21. 21.
    Myerson RJ, Garofalo MC, El Naqa I, et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys. 2009;74:824–30.CrossRefPubMedGoogle Scholar
  22. 22.
    Camma C, Giunta M, Fiorica F, Paglioaro L, Craxi A, Cottone M. Preoperative radiotherapy for resectable rectal cancer. JAMA. 2000;284:1008–15.CrossRefPubMedGoogle Scholar
  23. 23.
    Wong RKS, Tandan V, De Silva S, et al. Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst Rev. 2007;18(2):CD002102. John Wiley & SonsGoogle Scholar
  24. 24.
    Wiltshire KL, Ward IG, Swallow C, et al. Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: effect of dose escalation on pathologic complete response, local recurrence-free survival, disease-free survival, and overall survival. Int J Radiat Oncol Biol Phys. 2006;64:709–16.CrossRefPubMedGoogle Scholar
  25. 25.
    Ortholan C, Romestaing P, Chapet O, et al. Correlation in rectal cancer between clinical tumor response after neoadjuvant radiotherapy and sphincter or organ preservation: 10-year results of the Lyon R 96-02 randomized trial. Int J Radiat Oncol Biol Phys. 2012;83:165–71.CrossRefGoogle Scholar
  26. 26.
    Jakobsen A, Ploen J, Vuong T, Appelt A, Lindeberg J, Rafaelsen RS. The dose-effect relationship in chemoradiation of locally advance rectal cancer. A randomized trial comparing two radiation doses. Int J Radiat Oncol Biol Phys. November 2012;84(4):950–4.CrossRefGoogle Scholar
  27. 27.
    Gunderson L, Willettt C, Calvo FA, Harrison L. Intraoperative irradiation, Current clinical oncology. Second ed. New York: Humana Press.Google Scholar
  28. 28.
    Dubois J-B, Bussieres E, Richaud P, et al. Intra-operative radiotherapy of rectal cancer: results of the French multi-institutional randomized study. Radiother Oncol. 2011;98:298–303.CrossRefPubMedGoogle Scholar
  29. 29.
    Garofalo M, Moughan J, Hong T, et al. RTOG 0822: a phase II study of preoperative (PREOP) chemoradiotherapy (CRT) utilizing IMRT in combination with capecitabine (C) and oxaliplatin (O) for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2011;81(2):S3–4. abstract # 6CrossRefGoogle Scholar
  30. 30.
    Vuong T, Niazi T, Letellier F, et al. A dose escalation phase II study using intensity modulated radiation therapy (IMRT) and concurrent chemotherapy for patients with advanced rectal cancer and magnetic resonant imaging (MRI) defined positive circumferential radial margins (CRM+). Int J Radiat Oncol Biol Phys. 2011;81(2.) Abstract # 252Google Scholar
  31. 31.
    Vuong T, Belliveau PJ, Michel RP, et al. Conformal preoperative endorectal brachytherapy treatment for locally advanced rectal cancer: early results of a phase I/II study. Dis Colon Rectum. 2002;45:1486–93. discussion 1493-5CrossRefPubMedGoogle Scholar
  32. 32.
    Vuong T, Richard C, Niazi T, et al. High dose rate endorectal brachytherapy for patients with curable rectal cancer. Semin Colon Rectal Surg. 2010;21:115–9.CrossRefGoogle Scholar
  33. 33.
    Vuong T, Niazi T, Devic S: Role of endoluminal brachytherapy for rectal cancer: current status and challenges. Proceedings of ESTRO 3rd Forum, 24–28 April 2014.Google Scholar
  34. 34.
    Breugom AJ, Vermeer TA, van den Broek CBM, et al. Effect of preoperative treatment strategies on the outcome of patients with clinical T3, non-metastasized rectal cancer: a comparison between Dutch and Canadian expert centers. Eur J Surg Oncol. 2015;41(8):1039–44.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Japan 2018

Authors and Affiliations

  1. 1.Division of Radiation OncologyJewish General HospitalMontrealCanada

Personalised recommendations